Skip to main content
. 2017 Sep;9(9):2923–2934. doi: 10.21037/jtd.2017.07.107

Figure 3.

Figure 3

Kaplan-Meier survival curves of progression-free survival between chemotherapy alone and chemotherapy plus gefitinib (A) in patients with EGFRT790M-negative mutations (3.5 vs. 6.6 months, P=0.011), (B) in patients with EGFRT790M-positive mutations (5.5 vs. 5.0 months, P=0.520) and (C) in patients with unknown T790M mutational status (3.0 vs. 2.0 months, P=0.323).